Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

47.00 +2.36 (+5.29%)
Streaming Delayed Price Updated: 1:27 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Palvella Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Wider Q2 2025 Loss, Stock Drops 13% Despite Clinical Progress
Palvella Therapeutics (PVLA) reported a Q2 2025 net loss of $0.86 per share, missing estimates. Revenue was $0.0 as expected, with $70.4M cash on hand. Stock fell 13% pre-market despite clinical... 
Via Chartmill
Palvella Posts Cash Gain and Trial Wins
Via The Motley Fool
Topics Intellectual Property
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
Earnings Scheduled For August 14, 2025
 
Via Benzinga
Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
Earnings Scheduled For May 15, 2025
 
Via Benzinga
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of
From Palvella Therapeutics Inc.
Via GlobeNewswire
This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology
Presentation to highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN™ rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations 
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
Earnings Scheduled For March 31, 2025
 
Via Benzinga
Pavella - Undiscovered Biotechnology Stock
The company focuses on developing therapies for rare genetic skin diseases, with its lead product QTORIN rapamycin in advanced clinical trials. 
Via Talk Markets
Topics Stocks / Equities
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
From Palvella Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.